Sandoz Gains Rights To Two US Injectables
Further Signal Of Intent For US Sterile Injectables Strategy
With the $1bn deal to transfer its US dermatology and orals solids operations to Aurobindo still awaiting completion, Sandoz is expanding its portfolio of sterile injectables - a key area of focus for the company - by acquiring the rights to two products from BE Pharmaceuticals.
